---
title: "Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284954947.md"
description: "Regeneron Pharmaceuticals (NASDAQ:REGN) has delivered an average annual return of 21.11% over the past 20 years, outperforming the market by 12.27%. With a current market capitalization of $73.81 billion, a $100 investment in REGN stock two decades ago would now be worth $4,539.94, highlighting the significant impact of compounded returns on investment growth."
datetime: "2026-05-01T23:31:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284954947.md)
  - [en](https://longbridge.com/en/news/284954947.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284954947.md)
---

# Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 12.27% on an annualized basis producing an average annual return of 21.11%. Currently, Regeneron Pharmaceuticals has a market capitalization of $73.81 billion.

**Buying $100 In REGN:** If an investor had bought $100 of REGN stock 20 years ago, it would be worth **$4,539.94** today based on a price of $704.00 for REGN at the time of writing.

### Regeneron Pharmaceuticals's Performance Over Last 20 Years

![comp_fig](https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1777678266_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg)

Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.

_This article was generated by Benzinga's automated content engine and reviewed by an editor._

### Related Stocks

- [REGN.US](https://longbridge.com/en/quote/REGN.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)

## Related News & Research

- [Regeneron Sinks 10% on Failed Phase 3 Melanoma Trial. What Comes Next for REGN Stock.](https://longbridge.com/en/news/286811938.md)
- [Leerink Partners Reiterates "Market Perform" Rating for Regeneron Pharmaceuticals (NASDAQ:REGN)](https://longbridge.com/en/news/286773280.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Regeneron Announces Strategic Collaboration With Parabilis Medicines To Advance Novel Antibody-Helicon Conjugates Across Multiple Therapeutic Areas](https://longbridge.com/en/news/286759146.md)
- [Regeneron's Phase 3 Melanoma Trial Shows Numeric PFS Benefit But Misses Statistical Significance](https://longbridge.com/en/news/286662524.md)